A consortium of cannabis experts at the Drug Science Medical Cannabis Working Group (MCWG) have recently announced a partnership with the first British producer of pharmaceutical oils and isolates.
Avida Global will join MCWG to facilitate the process for medical cannabis access for patients in the UK, which has been limited since it was legalised in November 2018.
Founder of Drug Science, Professor David Nutt stated, “Having Avida Global as part of the team gives us an opportunity to collaborate with much of the exciting clinical research work, they are undertaking in the UK, Israel and Colombia.”
Drug Science is an integral part of the international cannabis community, providing a scientific and political UK approach to medical cannabis developments. They prompted the first World Health Organisation (WHO) report into cannabis for over 80 years, as well as helping to reform the cannabis law in South Africa.
The shared aim of this partnership is to provide greater access to medical cannabis in the UK.
CEO of Drug Science, David Badcock said, “We are delighted that Avida Global have joined the Drug Science Medical Cannabis Working Group. Our shared vision, which will accelerate access of medical cannabis to patients who need it the most, will be greatly enhanced by the support provided by the Avida Global team.”